Rethinking How Employers Can Support the Obesity Patient Journey

PROPEL Study Overview from PCORI

December 9, 2pm ET



Webinar Agenda

- Welcome/Introduction Neil Goldfarb
- PCORI Update Rachel Mosbacher
- Peter Katzmarzyk, MD Featured PCORI-funded Study
- Ava Zebrick | Patient Advocate Advisor to PCORI-funded Study
- Brief Comments from PCORI Study Team focused on Bariatric Surgery Effectiveness
- Questions/Discussion led by Neil Goldfarb
- Questions from the Audience
- Pop up Survey
- Thank you



Welcome | Introduction



Neil Goldfarb
Greater Philadelphia Business Coalition on Health



Rachel Mosbacher, MPA
Senior Program Officer, Engagement Awards
PCORI



PCORI/ CER Principal Investigator



Ava J. Zebrick
Ochsner Medical Center
PCORI Patient Advocate Advisor



Peter T. Katzmarzyk, PhD

Pennington Biomedical

Research Center; PCORI Principal Investigator



Weight Loss in Underserved Patients in Primary Care Settings

Peter T. Katzmarzyk, PhD, FTOS, FAHA, FACSM
Pennington Biomedical Research Center, Baton Rouge, LA






Background

Obesity affects ~ 42% of US adults¹

The economic costs of obesity in the US are estimated to be \$1.4 trillion, or 6.8% of GDP²



The **primary aim** of this trial was to develop and test the effectiveness of a 24-month, <u>patient-centered</u>, <u>pragmatic</u> and scalable obesity treatment program delivered within primary care, inclusive of an underserved population.

Intensive Lifestyle Intervention (ILI)

- Patients received weekly counselling sessions (16 inperson/6 telephone) in the first 6 months, followed by monthly sessions (alternating in-person/telephone) for the remaining 18 months.
- All sessions were delivered by health coaches embedded in the primary care clinics.





Usual Care (UC) Group



- Patients received routine care from their primary care team throughout the trial
- Patients received 6 newsletters covering health-related topics and community resources

The NEW ENGLAND JOURNAL of MEDICINE

ESTABLISHED IN 1812

SEPTEMBER 3, 2020

VOL. 383 NO. 10

Weight Loss in Underserved Patients — A Cluster-Randomized Trial

Peter T. Katzmarzyk, Ph.D., Corby K. Martin, Ph.D., Robert L. Newton, Jr., Ph.D., John W. Apolzan, Ph.D., Connie L. Arnold, Ph.D., Terry C. Davis, Ph.D., Eboni G. Price-Haywood, M.D., Kara D. Denstel, M.P.H., Emily F. Mire, M.S., Tina K. Thethi, M.D., Phillip J. Brantley, Ph.D., William D. Johnson, Ph.D., Vivian Fonseca, M.D., Jonathan Gugel, M.D., Kathleen B. Kennedy, Ph.D., Carl J. Lavie, M.D., Daniel F. Sarpong, Ph.D., and Benjamin Springgate, M.D.

Patient Characteristics

N = 803

Age: 49.4 y (20 to 74 y)

BMI: 37.2 kg/m² (29 to 49.5 kg/m²)

% African American: 67.2%

% Income Below \$20,000: 41.2%


% Low Health Literacy (≤8th grade): 30.8%

% Food Insecure: 30.8%

Weight Loss Outcomes

	UC	ILI	Difference	
Change in Body Weight (%)				
At 6 months	-0.47 (-1.40, 0.46)	-7.34 (-8.23, -6.45)	-6.86 (-8.05, -5.68)	
At 12 months	-0.59 (-1.61, 0.43)	-6.75 (-7.72, -5.78)	-6.16 (-7.47, -4.85)	
At 18 months	-0.40 (-1.44, 0.64)	-5.62 (-6.61, -4.63)	-5.22 (-6.57, -3.88)	
At 24 months	-0.48 (-1.57, 0.61)	-4.99 (-6.02, -3.96)	-4.51 (-5.93, -3.10)	
Change in Body Weight (kg)				
At 6 months	-0.83 (-1.82, 0.17)	-7.81 (-8.77, -6.85)	-6.98 (-8.26, -5.71)	
At 12 months	-0.99 (-2.08, 0.09)	-7.22 (-8.25, -6.19)	-6.23 (-7.63, -4.83)	
At 18 months	-0.82 (-1.92, 0.29)	-6.07 (-7.12, -5.02)	-5.26 (-6.69, -3.82)	
At 24 months	-0.91 (-2.07, 0.24)	-5.43 (-6.52, -4.34)	-4.51 (-6.01, -3.02)	
Change in Waist Circumference (cm)				
At 6 months	-0.99 (-1.93, -0.05)	-6.84 (-7.75, -5.93)	-5.85 (-7.04, -4.66)	
At 12 months	-0.68 (-1.70, 0.33)	-6.63 (-7.61, -5.66)	-5.95 (-7.25, -4.65)	
At 18 months	0.21 (-0.82, 1.24)	-5.33 (-6.32, -4.34)	-5.54 (-6.86, -4.22)	
At 24 months	0.71 (-0.35, 1.78)	-4.42 (-5.44, -3.41)	-5.13 (-6.50, -3.77)	
	9000 40 8	no e-man 6-920		

Percentage of Patients Achieving ≥5% and ≥10% Weight Loss



Patient-Reported Outcomes

<u>Variable</u>	UC	ILI	Difference
Change in Weight-related C			
At 6 months	3.02 (1.14, 4.90)	10.55 (8.69, 12.41)	7.53 (5.18, 9.88)
At 12 months	3.56 (1.61, 5.50)	11.14 (9.23, 13.06)	7.59 (5.15, 10.03)
At 24 months	4.36 (2.34, 6.39)	11.02 (9.04, 13.00)	6.66 (4.10, 9.21)
Change in IWQOL-L Physical Function			
At 6 months	2.71 (-0.03, 5.45)	13.35 (10.70, 16.00)	10.64 (7.17, 14.10)
At 12 months	3.20 (0.44, 5.96)	13.59 (10.92, 16.27)	10.39 (6.89, 13.89)
At 24 months	4.11 (1.24, 6.97)	12.31 (9.55, 15.06)	8.20 (4.56, 11.84)
Change in IWQOL-L Self Esteem			
At 6 months	4.69 (2.20, 7.17)	12.20 (9.67, 14.72)	7.51 (4.44, 10.58)
At 12 months	5.86 (3.21, 8.50)	13.74 (11.07, 16.40)	7.88 (4.57, 11.19)
At 24 months	7.62 (4.88, 10.36)	14.39 (11.66, 17.12)	6.77 (3.32, 10.21)



Patient-Reported Outcomes

<u>Variable</u>	UC	ILI	Difference
Change in IWQOL-L Sexual			
At 6 months	2.02 (-1.05, 5.08)	12.19 (9.05, 15.33)	10.18 (6.37, 13.98)
At 12 months	3.19 (0.12, 6.27)	12.20 (9.04, 15.36)	9.01 (5.18, 12.84)
At 24 months	4.49 (1.18, 7.80)	14.32 (11.00, 17.65)	9.83 (5.68, 13.99)
Change in IWQOL-L Public Distress			
At 6 months	2.42 (-0.12, 4.96)	4.76 (2.29, 7.22)	2.33 (-0.88, 5.54)
At 12 months	2.39 (-0.19, 4.96)	5.95 (3.46, 8.44)	3.56 (0.31, 6.82)
At 24 months	2.41 (-0.20, 5.02)	5.38 (2.86, 7.89)	2.97 (-0.34, 6.27)
Change in IWQOL-L Work/Daily Activity			
At 6 months	2.69 (0.57, 4.82)	5.41 (3.29, 7.53)	2.72 (0.07, 5.37)
At 12 months	1.83 (-0.38, 4.03)	5.67 (3.48, 7.86)	3.84 (1.08, 6.60)
At 24 months	1.47 (-0.83, 3.76)	5.48 (3.22, 7.75)	4.02 (1.12, 6.91)

Relevance to Employers

- The annual costs of having obesity are approximately \$4,879 for a woman and \$2,646 for a man¹
- Obesity-attributable absenteeism among American workers costs the nation an estimated \$8.65 billion per year (2012), or 7-12% of total absenteeism costs²



Integration into Care

- The AHA/ACC/TOS Obesity Guidelines are emphatic that intensive behavioral intervention is the cornerstone of weight loss
- This approach should be balanced with other approaches such as bariatric surgery and pharmacotherapy based on the patient
- More work is need to integrate these approaches into primary care and other heath care settings

Conclusions



Obesity is a significant public health concern, especially in underserved populations.



Clinically significant weight loss in possible among low-income primary care patients using a high-intensity, culturally adapted intervention.



Bring the intervention to "where" it is needed, taking into account patient preferences, attitudes, socioeconomic status, health literacy and culture.

Acknowledgements

Pennington Biomedical

Kara Denstel
Emily Mire
Ken Singletary
Cheryl Lewis
Emily Braun
Mary Williams
Lisa Landry

PROPEL Stakeholders

Gary Wiltz (Teche Action Board)
Willie White III (David Raines CHCs)
Michael G. Griffith (Daughters of Charity)
Robert Post (Daughters of Charity)

PROPEL Investigators

Corby Martin
John Apolzan
Robert Newton, Jr.
William Johnson
Phil Brantley
Tina Thethi (Tulane)
Vivian Fonseca (Tulane)
Jonathon Gugel (Tulane)
Eboni Price-Haywood (Ochsner)
Chip Lavie (Ochsner)
Terry Davis (LSUHSC-S)
Connie Arnold (LSUHSC-S)
Ben Springgate (LSUHSC-NO)
Kathleen Kennedy (Xavier)
Daniel Sarpong (Xavier)

PROPEL Staff

Allison Davis Lindsay Hall **Taylor Ayers** Karissa Neubig Kelly Lynch Stephanie Authement Shiguita Brooks **Kevin Sanders** Leslie Forest Cristalyn Reynolds Angelle Graham Danielle Burrell Jill Hancock **Tabitha Gray** Hillary Young Ekambi Shelton **Brittany Neyland Brittany Molinere** Stephanie Rincones







Acknowledgements

PROPEL is supported by the Patient-Centered Outcomes Research Institute (PCORI) Contract #OB–1402– 10977 (PI: P. Katzmarzyk).

This work was completed prior to Dr Price-Haywood's appointment to the PCORI Board of Governors.

Additional support was provided by 1 U54 GM104940 from the National Institute of General Medical Sciences of the National Institutes of Health that funds the Louisiana Clinical and Translational Science Center, and NORC Center Grant # P30DK072476 entitled "Nutrition and Metabolic Health Through the Lifespan" sponsored by NIDDK.

Support for Obesity Patients

Why I'm here








Start with "Who" and "What"

What is obesity?

What is Obesity & Severe Obesity?

Obesity is a treatable disease that is a worldwide health concern associated with having an excess amount of body fat. It is caused by genetic and environmental factors and can be difficult to control through dieting alone. Obesity is diagnosed by a healthcare provider and is classified as having a body mass index (BMI) of 30 or greater. Nearly 40 percent of Americans have obesity.

Obesity Tug-of-war




Changing the dialogue

Self-Talk <u>Without</u> Understanding What Obesity Is	With the Knowledge & Understanding	
I am obese.	I am a person who is affected by obesity.	
It is my fault. I did this to myself.	Obesity is a complex disease with genetic, environmental, and behavioral causes.	
My weight is solely my responsibility.	Obesity is a chronic <u>disease with biological processes</u> that make it <u>resistant to treatment</u> and that contribute to relapse.	
Weight loss or gain is determined by choices and willpower. If I fail to make enough changes and control my weight, it is my personal failure.	My weight matters for my health, and I need help from healthcare professionals who understand the disease of obesity in order to treat it and help me manage my weight.	
I know how to lose weight. I have done it before. This time I didn't do the right and I didn't do enough. I knew better, and I should feel ashamed.	Obesity is complex, everybody's body is different, and every person is complicated. Managing weight is not simple, and it's difficult. The more information, support, and "tools in the toolbox" I have, the better.	


Obesity Tug-of-war

As patients, when we understand obesity, we are more likely to:

- Feel relief from internalized bias
- Reach out for resources and support
- Engage and partner with our healthcare team



Healthcare Support




- o **Intensive Behavioral Therapy** for obesity by professionals who understand the disease and are appropriately trained
- Covered visits with Board Certified Obesity Medicine Specialists (MDs)
- Coverage for FDA approved anti-obesity pharmacotherapy
- Affordable and comprehensive metabolic surgery program per guidelines of the American Medical Association (AMA), American Board of Obesity Medicine (ABOM), and American Society for Metabolic and Bariatric Surgery (ASMBS)
 - Not limited to 1 lifetime procedure
 - No conditional half-year waiting period
 - No requirement of "successful" weight loss prior to approval

Employer Sponsored Social Support



- o Education about weight bias in the workplace
- O Corporate Wellness*
 - Specialist led support groups
 - O Peer led support groups



Going forward

Ava Zebrick, MSHCM ajzebrick@gmail.com



Special Guests – PCORI Researchers – Comments/Reactions



David E. Arterburn, MD, MPH
Senior Investigator,
Kaiser Permanente Washington
Health Research Institute



Neely A. Williams, M.Div., Ed.D

Director of Community Engagement


TN CEAL



Kathleen McTigue, MD, MPH Associate Professor of Medicine & Clinical and Translational Science



Discussion led by Neil Goldfarb / Questions from the Attendees.




Please add your questions to the Q&A box



Resources

Novo Nordisk Rethink Obesity®
PCORI PROPEL Study
PCORI Obesity Surgery study
GPBCH: Prescription Weight Loss Therapies
The New Science of Obesity, National Alliance
STOP Mental Health, Obesity, and Racial Disparities
STOP Mental Health Fact Sheet
Link Between Obesity and Mental Health
Parity Infographic



Infographic for Employees (Patients)



Action Brief for Employers (coming soon)



Thank you and Popup Survey



A survey will appear in your web browser after the Webinar. You could complete it immediately or a survey link will be sent to your email. Completed survey responses must be in by 12 PM ET on December 13.

